A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525923-26-00

Enrollment

125

Registered

2026-08-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderately to Severely Active Ulcerative Colitis

Brief summary

Clinical remission at Week 48

Interventions

DRUGJNJ-78934804

DRUGGuselkumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clinical remission at Week 48	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 5, 2026